Question 1

What is Guselkumab?

Accepted Answer

Guselkumab is a Other.

Question 2

How often does Guselkumab appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Guselkumab first tracked by Ergen?

Accepted Answer

First tracked on May 28, 2026.

Question 4

When was Guselkumab last mentioned in news?

Accepted Answer

Last active on May 29, 2026.

Question 5

What is Guselkumab's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Guselkumab in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Guselkumab?

Accepted Answer

FDA approves TREMFYA label expansion (May 28, 2026, 6 articles).

Question 8

How did the "FDA approves TREMFYA label expansion" event impact Guselkumab?

Accepted Answer

Guselkumab, a drug developed by Johnson & Johnson, received an expanded FDA label, highlighting its unique ability to inhibit structural joint damage in psoriatic arthritis patients, making it a more competitive treatment option.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.